Related Experiment Videos
p53 gene therapy for esophageal cancer
Hideaki Shimada1, Hisahiro Matsubara, Takenori Ochiai
1Department of Academic Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Abstract:
Despite improvement of surgical treatment and application of multimodality therapies to advanced esophageal cancer, the prognosis is extremely poor for patients with unresectable tumors. Based on the genetic background of esophageal cancer, we have developed various gene therapy strategies against human esophageal cancer. In this article, we review molecular events of esophageal cancer and p53 gene therapy approaches for its treatment. First, we analyzed p53 genetic alterations and angiogenesis in esophageal cancer. Second, we tested a p53 recombinant adenoviral vector (Ad5CMV-p53). Significant growth suppression was observed following infection with Ad5CMV-p53 in human esophageal cancer cell lines. This observation suggests that Ad5CMV-p53 may be a potentially effective therapeutic agent for locally advanced esophageal cancer. Promising avenues for investigation include double gene therapy and adjuvant use of gene therapy with radiation therapy. Third, based on recent reports of clinical trials of p53 gene therapy for lung cancer and head and neck cancer, we developed a clinical protocol for p53 gene therapy for unresectable advanced esophageal cancer. This clinical trial was planned to evaluate vector tolerability and efficacy. Up to December 1, 2001, four patients were enrolled in this phase I/II trial. No serious adverse events related to Ad5CMV-p53 have occurred so far in these patients, and the trial has been safely conducted.
Insights
p53 gene therapy using Ad5CMV-p53 shows promise for treating advanced esophageal cancer. Early clinical trials indicate the therapy is safe and well-tolerated, suggesting potential for unresectable tumors.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Advanced esophageal cancer with unresectable tumors has a poor prognosis despite current treatments.
- Understanding the molecular events and genetic alterations in esophageal cancer is crucial for developing new therapies.
- p53 gene therapy presents a novel strategy targeting the genetic basis of esophageal cancer.
Purpose of the Study:
- To review molecular events in esophageal cancer, focusing on p53 alterations and angiogenesis.
- To evaluate the efficacy of a p53 recombinant adenoviral vector (Ad5CMV-p53) in human esophageal cancer cell lines.
- To develop and initiate a clinical trial for p53 gene therapy in patients with unresectable advanced esophageal cancer.
Main Methods:
- Analysis of p53 genetic alterations and angiogenesis in esophageal cancer.
- In vitro testing of Ad5CMV-p53 in human esophageal cancer cell lines.
- Development of a clinical protocol for a phase I/II trial of p53 gene therapy for unresectable advanced esophageal cancer.
Main Results:
- Ad5CMV-p53 infection demonstrated significant growth suppression in esophageal cancer cell lines.
- The phase I/II clinical trial enrolled four patients with unresectable advanced esophageal cancer.
- No serious adverse events related to Ad5CMV-p53 were reported in the initial trial participants, indicating safe conduct.
Conclusions:
- Ad5CMV-p53 is a potentially effective therapeutic agent for locally advanced esophageal cancer.
- Further research into combination therapies, such as double gene therapy or adjuvant gene therapy with radiation, is warranted.
- The p53 gene therapy clinical trial has been safely conducted, supporting its potential for treating unresectable advanced esophageal cancer.